Novo Nordisk A/S (NVO) EV/EBIT Ratio: 9.20x
Is Novo Nordisk A/S’s EV/EBIT ratio high or low?
Novo Nordisk A/S's EV/EBIT ratio of 9.20x is 64% below its 5-year average of 25.47x, near the low end of its 5-year range (8.72x–41.62x).
As of Wednesday, June 17, 2026. 21.87% below its 12-month average of 11.78x.
NVO EV/EBIT Ratio Chart
NVO Average EV/EBIT Ratio Chart
NVO Current vs Average EV/EBIT Ratio Chart
NVO EV/EBIT Ratio Metrics
EV/EBIT RATIO
9.20x
EV/EBIT RATIO AVG TTM
11.78x
EV/EBIT RATIO AVG 3Y
24.26x
EV/EBIT RATIO AVG 5Y
25.47x
EV/EBIT RATIO AVG 10Y
20.91x
EV/EBIT RATIO AVG 15Y
18.78x
EV/EBIT RATIO AVG 20Y
18.05x
CURRENT VS TTM AVG
-21.87%
CURRENT VS 3Y AVG
-62.08%
CURRENT VS 5Y AVG
-63.88%
CURRENT VS 10Y AVG
-55.99%
CURRENT VS 15Y AVG
-51.02%
CURRENT VS 20Y AVG
-49.04%
NVO Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 9.20x | 11.78x | 24.26x | 25.47x |
| Amgen Inc. (AMGN)vs › | $189.27B | 20.04x | 24.69x | 26.24x | 23.37x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $177.08B | 26.99x | 28.32x | 30.54x | 28.33x |
| Gilead Sciences, Inc. (GILD)vs › | $157.69B | 14.98x | 18.25x | 42.71x | 31.50x |
| Abbott Laboratories (ABT)vs › | $156.41B | 22.21x | 27.82x | 30.31x | 27.84x |
| Pfizer Inc. (PFE)vs › | $148.76B | 14.26x | 12.26x | 29.89x | 23.36x |
| Intuitive Surgical, Inc. (ISRG)vs › | $148.26B | 45.87x | 62.83x | 72.91x | 67.67x |
| Danaher Corporation (DHR)vs › | $128.72B | 27.27x | 30.59x | 32.52x | 29.67x |
| CVS Health Corporation (CVS)vs › | $127.54B | 33.12x | 29.13x | 19.94x | 18.81x |
| Stryker Corporation (SYK)vs › | $119.06B | 24.55x | 28.21x | 30.49x | 30.14x |
Novo Nordisk A/S EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The EV/EBIT ratio for NVO stock is 9.20x.
- Is Novo Nordisk A/S's EV/EBIT ratio high or low?
- Novo Nordisk A/S's EV/EBIT ratio of 9.20x is 64% below its 5-year average of 25.47x, near the low end of its 5-year range (8.72x–41.62x).
- What is the TTM average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The TTM average EV/EBIT ratio for NVO stock is 11.78x.
- What is the 3Y average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The 3Y average EV/EBIT ratio for NVO stock is 24.26x.
- What is the 5Y average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The 5Y average EV/EBIT ratio for NVO stock is 25.47x.
- What is the 10Y average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The 10Y average EV/EBIT ratio for NVO stock is 20.91x.
- What is the 15Y average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The 15Y average EV/EBIT ratio for NVO stock is 18.78x.
- What is the 20Y average EV/EBIT ratio for Novo Nordisk A/S (NVO)?
- The 20Y average EV/EBIT ratio for NVO stock is 18.05x.
Novo Nordisk A/S EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-16 | 9.20x |
| 2026-06-15 | 9.27x |
| 2026-06-12 | 9.26x |
| 2026-06-11 | 9.28x |
| 2026-06-10 | 9.06x |
| 2026-06-09 | 8.94x |
| 2026-06-08 | 8.72x |
| 2026-06-05 | 9.09x |
| 2026-06-04 | 9.24x |
| 2026-06-03 | 8.90x |
| 2026-06-02 | 9.08x |
| 2026-06-01 | 9.30x |
| 2026-05-29 | 9.59x |
| 2026-05-28 | 9.58x |
| 2026-05-27 | 9.39x |
| 2026-05-26 | 9.32x |
| 2026-05-22 | 9.47x |
| 2026-05-21 | 9.36x |
| 2026-05-20 | 9.49x |
| 2026-05-19 | 9.34x |
| 2026-05-18 | 9.34x |
| 2026-05-15 | 9.43x |
| 2026-05-14 | 9.63x |
| 2026-05-13 | 9.88x |
| 2026-05-12 | 9.86x |
| 2026-05-11 | 9.75x |
| 2026-05-08 | 9.69x |
| 2026-05-07 | 9.63x |
| 2026-05-06 | 9.63x |
| 2026-05-05 | 11.03x |
| 2026-05-04 | 10.92x |
| 2026-05-01 | 10.80x |
| 2026-04-30 | 10.43x |
| 2026-04-29 | 9.99x |
| 2026-04-28 | 10.19x |
| 2026-04-27 | 10.20x |
| 2026-04-24 | 10.19x |
| 2026-04-23 | 9.59x |
| 2026-04-22 | 9.73x |
| 2026-04-21 | 9.79x |
| 2026-04-20 | 10.03x |
| 2026-04-17 | 10.04x |
| 2026-04-16 | 10.13x |
| 2026-04-15 | 10.11x |
| 2026-04-14 | 9.77x |
| 2026-04-13 | 9.46x |
| 2026-04-10 | 9.36x |
| 2026-04-09 | 9.34x |
| 2026-04-08 | 9.38x |
| 2026-04-07 | 9.22x |
| 2026-04-06 | 9.17x |
| 2026-04-02 | 9.24x |
| 2026-04-01 | 9.12x |
| 2026-03-31 | 9.18x |
| 2026-03-30 | 8.85x |
| 2026-03-27 | 9.02x |
| 2026-03-26 | 9.10x |
| 2026-03-25 | 9.09x |
| 2026-03-24 | 9.22x |
| 2026-03-23 | 9.20x |
| 2026-03-20 | 9.13x |
| 2026-03-19 | 9.26x |
| 2026-03-18 | 9.34x |
| 2026-03-17 | 9.57x |
| 2026-03-16 | 9.60x |
| 2026-03-13 | 9.46x |
| 2026-03-12 | 9.47x |
| 2026-03-11 | 9.66x |
| 2026-03-10 | 9.63x |
| 2026-03-09 | 9.87x |
| 2026-03-06 | 9.60x |
| 2026-03-05 | 9.71x |
| 2026-03-04 | 9.58x |
| 2026-03-03 | 9.16x |
| 2026-03-02 | 9.41x |
| 2026-02-27 | 9.34x |
| 2026-02-26 | 9.38x |
| 2026-02-25 | 9.50x |
| 2026-02-24 | 9.60x |
| 2026-02-23 | 9.84x |
| 2026-02-20 | 11.61x |
| 2026-02-19 | 11.84x |
| 2026-02-18 | 12.02x |
| 2026-02-17 | 12.05x |
| 2026-02-13 | 12.10x |
| 2026-02-12 | 11.95x |
| 2026-02-11 | 11.91x |
| 2026-02-10 | 11.99x |
| 2026-02-09 | 12.05x |
| 2026-02-06 | 11.66x |
| 2026-02-05 | 10.68x |
| 2026-02-04 | 11.56x |
| 2026-02-03 | 12.26x |
| 2026-02-02 | 13.86x |
| 2026-01-30 | 13.97x |
| 2026-01-29 | 13.95x |
| 2026-01-28 | 14.18x |
| 2026-01-27 | 14.76x |
| 2026-01-26 | 15.00x |
| 2026-01-23 | 14.61x |
| 2026-01-22 | 14.61x |
| 2026-01-21 | 13.95x |
| 2026-01-20 | 14.26x |
| 2026-01-16 | 14.63x |
| 2026-01-15 | 13.45x |
| 2026-01-14 | 13.86x |
| 2026-01-13 | 14.02x |
| 2026-01-12 | 14.07x |
| 2026-01-09 | 13.83x |
| 2026-01-08 | 13.50x |
| 2026-01-07 | 13.33x |
| 2026-01-06 | 13.26x |
| 2026-01-05 | 13.00x |
| 2026-01-02 | 12.38x |
| 2025-12-31 | 12.04x |
| 2025-12-30 | 12.12x |
| 2025-12-29 | 12.18x |
| 2025-12-26 | 12.39x |
| 2025-12-24 | 12.42x |
| 2025-12-23 | 12.21x |
| 2025-12-22 | 11.41x |
| 2025-12-19 | 11.41x |
| 2025-12-18 | 11.30x |
| 2025-12-17 | 11.34x |
| 2025-12-16 | 11.61x |
| 2025-12-15 | 11.93x |
| 2025-12-12 | 11.88x |
| 2025-12-11 | 11.91x |
| 2025-12-10 | 11.63x |
| 2025-12-09 | 11.02x |
| 2025-12-08 | 11.11x |
| 2025-12-05 | 11.36x |
| 2025-12-04 | 11.39x |
| 2025-12-03 | 11.30x |
| 2025-12-02 | 11.26x |
| 2025-12-01 | 11.49x |
| 2025-11-28 | 11.70x |
| 2025-11-26 | 11.55x |
| 2025-11-25 | 11.18x |
| 2025-11-24 | 10.71x |
| 2025-11-21 | 11.31x |
| 2025-11-20 | 11.30x |
| 2025-11-19 | 11.62x |
| 2025-11-18 | 11.29x |
| 2025-11-17 | 11.50x |
| 2025-11-14 | 11.45x |
| 2025-11-13 | 11.65x |
| 2025-11-12 | 11.90x |
| 2025-11-11 | 11.65x |
| 2025-11-10 | 10.93x |
| 2025-11-07 | 10.87x |
| 2025-11-06 | 11.06x |
| 2025-11-05 | 11.50x |
| 2025-11-04 | 10.81x |
| 2025-11-03 | 10.99x |
| 2025-10-31 | 11.07x |
| 2025-10-30 | 11.19x |
| 2025-10-29 | 11.47x |
| 2025-10-28 | 11.62x |
| 2025-10-27 | 11.79x |
| 2025-10-24 | 11.81x |
| 2025-10-23 | 11.87x |
| 2025-10-22 | 11.90x |
| 2025-10-21 | 12.19x |
| 2025-10-20 | 12.40x |
| 2025-10-17 | 12.11x |
| 2025-10-16 | 12.47x |
| 2025-10-15 | 12.60x |
| 2025-10-14 | 12.59x |
| 2025-10-13 | 12.77x |
| 2025-10-10 | 12.65x |
| 2025-10-09 | 13.02x |
| 2025-10-08 | 13.22x |
| 2025-10-07 | 13.09x |
| 2025-10-06 | 13.22x |
| 2025-10-03 | 13.22x |
| 2025-10-02 | 13.03x |
| 2025-10-01 | 13.12x |
| 2025-09-30 | 12.34x |
| 2025-09-29 | 12.35x |
| 2025-09-26 | 12.37x |
| 2025-09-25 | 12.46x |
| 2025-09-24 | 13.03x |
| 2025-09-23 | 13.20x |
| 2025-09-22 | 13.45x |
| 2025-09-19 | 13.59x |
| 2025-09-18 | 13.69x |
| 2025-09-17 | 12.92x |
| 2025-09-16 | 12.71x |
| 2025-09-15 | 12.37x |
| 2025-09-12 | 12.21x |
| 2025-09-11 | 12.09x |
| 2025-09-10 | 12.11x |
| 2025-09-09 | 12.09x |
| 2025-09-08 | 12.09x |
| 2025-09-05 | 12.29x |
| 2025-09-04 | 12.48x |
| 2025-09-03 | 12.61x |
| 2025-09-02 | 12.53x |
| 2025-08-29 | 12.55x |
| 2025-08-28 | 12.47x |
| 2025-08-27 | 12.54x |
| 2025-08-26 | 12.31x |
| 2025-08-25 | 12.52x |
| 2025-08-22 | 12.66x |
| 2025-08-21 | 12.34x |
| 2025-08-20 | 12.09x |
| 2025-08-19 | 12.19x |
| 2025-08-18 | 11.98x |
| 2025-08-15 | 11.69x |
| 2025-08-14 | 11.38x |
| 2025-08-13 | 11.37x |
| 2025-08-12 | 11.14x |
| 2025-08-11 | 11.15x |
| 2025-08-08 | 11.41x |
| 2025-08-07 | 10.92x |
| 2025-08-06 | 10.21x |
| 2025-08-05 | 11.37x |
| 2025-08-04 | 11.73x |
| 2025-08-01 | 11.59x |
| 2025-07-31 | 11.33x |
| 2025-07-30 | 12.01x |
| 2025-07-29 | 12.90x |
| 2025-07-28 | 16.34x |
| 2025-07-25 | 16.95x |
| 2025-07-24 | 16.73x |
| 2025-07-23 | 16.57x |
| 2025-07-22 | 15.83x |
| 2025-07-21 | 15.41x |
| 2025-07-18 | 15.27x |
| 2025-07-17 | 15.49x |
| 2025-07-16 | 15.89x |
| 2025-07-15 | 15.93x |
| 2025-07-14 | 16.32x |
| 2025-07-11 | 16.32x |
| 2025-07-10 | 16.80x |
| 2025-07-09 | 16.49x |
| 2025-07-08 | 16.48x |
| 2025-07-07 | 16.41x |
| 2025-07-03 | 16.38x |
| 2025-07-02 | 16.52x |
| 2025-07-01 | 16.52x |
| 2025-06-30 | 16.34x |
| 2025-06-27 | 16.23x |
| 2025-06-26 | 16.04x |
| 2025-06-25 | 15.96x |
| 2025-06-24 | 16.73x |
| 2025-06-23 | 16.50x |
| 2025-06-20 | 17.43x |
| 2025-06-18 | 17.48x |
| 2025-06-17 | 17.56x |
| 2025-06-16 | 18.17x |
| 2025-06-13 | 18.81x |
| 2025-06-12 | 19.09x |
| 2025-06-11 | 18.56x |
| 2025-06-10 | 18.69x |
| 2025-06-09 | 17.81x |
| 2025-06-06 | 17.62x |
| 2025-06-05 | 17.17x |
| 2025-06-04 | 17.03x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar